Phenotypes associated with this allele

• Allele Symbol: Ivns1abp^tm1Htno
• Allele Name: targeted mutation 1, Masahiko Hatano
• Allele ID: MGI:4820513
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Ivns1abp^tm1Htno/Ivns1abp^tm1Htno	involves: 129S1/Sv * 129X1/SvJ * C57BL/6	MGI:4820514

Genotype
MGI:4820514

hm1

• Allelic Composition: Ivns1abp^tm1Htno/Ivns1abp^tm1Htno
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

increased susceptibility to xenobiotic induced morbidity/mortality ( J:162743 )

• 90% of doxorubicin-treated mice die within 4 weeks unlike 60% of similarly treated wild-type mice

preweaning lethality, incomplete penetrance ( J:162743 )

• fewer than expected mice are produced (no time of death or observation given)

homeostasis/metabolism

ascites ( J:162743 )

• in doxorubicin-treated mice

pleural effusion ( J:162743 )

• in doxorubicin-treated mice

increased susceptibility to xenobiotic induced morbidity/mortality ( J:162743 )

• 90% of doxorubicin-treated mice die within 4 weeks unlike 60% of similarly treated wild-type mice

increased physiological sensitivity to xenobiotic ( J:162743 )

• mice exhibit doxorubicin-induced cardiotoxicity with massive bilateral pleural effusion and ascites indicative of congestive heart failure, poor movement of left anterior ventricular wall, decreased left ventricular ejection fraction, and increased apoptotic cardiomyocytes compared with similarly treated wild-type mice

cardiovascular system

decreased cardiac muscle contractility ( J:162743 )

• in doxorubicin-treated mice

cellular

increased sensitivity to induced cell death ( J:162743 )

• mouse embryonic fibroblasts (MEF) treated with cytochalasin D exhibit apoptosis unlike similarly treated wild-type cells

• doxorubicin-treated MEFs exhibit increased apoptosis compared with similarly treated wild-type cells

increased cardiomyocyte apoptosis ( J:162743 )

• in doxorubicin-treated mice

muscle

decreased cardiac muscle contractility ( J:162743 )

• in doxorubicin-treated mice

increased cardiomyocyte apoptosis ( J:162743 )

• in doxorubicin-treated mice

respiratory system

pleural effusion ( J:162743 )

• in doxorubicin-treated mice